Before starting Namenda, ask whether the diagnosis and disease stage fit the drug, what benefit is realistic, and how kidney function affects the dose. Also ask about side effects, medication interactions, missed doses, and how the family will judge whether treatment helps. Namenda, the brand name for memantine, treats symptoms of moderate-to-severe dementia of the Alzheimer's type. It does not cure Alzheimer's or reverse the underlying brain-cell damage, according to the Alzheimer's Association medication guide.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Does the diagnosis and stage fit Namenda?
- What dose is appropriate?
- Which side effects should we prepare for?
- Could another medicine or condition raise the risk?
- How will we decide whether to continue?
Does the diagnosis and stage fit Namenda?
Ask the prescriber to confirm both the type of dementia and its stage. The DailyMed prescribing label identifies namenda for moderate-to-severe dementia of the Alzheimer's type.
Then ask what improvement is reasonably possible. The goal may be limited symptom improvement or stabilization, not restored memory or a return to earlier abilities. Useful questions include:.
- Which symptoms are we hoping to improve or stabilize?
- What changes would count as a meaningful benefit?
- When will we review whether treatment is meeting that goal?
- Who should record changes in memory, behavior, communication, or daily tasks?
What dose is appropriate?
Ask for a written dosing schedule. The labeled regimen begins at 5 mg once daily and increases by 5 mg no more often than weekly, reaching 10 mg twice daily, or 20 mg per day. Kidney function can change that target. For severe kidney impairment—defined in the label as creatinine clearance of 5–29 mL/min—the target is 5 mg twice daily.
Ask whether kidney function has been reviewed and whether the proposed dose reflects the result. Also clarify what to do after a missed dose. Do not double a single missed dose. If several days have been missed, contact the prescriber before restarting because the dose may need to be increased gradually again.
Which side effects should we prepare for?
Ask which reactions require a routine call and which require prompt medical attention. In controlled trials, the most common adverse reactions occurring in at least 5% of patients and more often than with placebo were dizziness, headache, confusion, and constipation. plan how the household will recognize and report these problems.
Dizziness or increased confusion may be especially important to notice in someone who moves around without assistance, while constipation may be missed unless a caregiver tracks it. Before the first dose, tell the prescriber about any previous reaction to memantine or the tablet's ingredients. A known allergy to either is a contraindication, meaning the medicine should not be used.
Could another medicine or condition raise the risk?
Bring a complete medication list, including nonprescription products, and ask the prescriber or pharmacist to review it. Namenda combined with the NMDA antagonists amantadine, ketamine, or dextromethorphan has not been systematically evaluated and requires caution. Some medicines and medical conditions can make urine more alkaline, reducing memantine clearance and raising drug levels.
Examples in the label include sodium bicarbonate, carbonic-anhydrase inhibitors, renal tubular acidosis, and severe urinary-tract infection. Namenda may also be prescribed with donepezil. A 24-week study cited in the label found a similar adverse-event profile for Namenda plus donepezil and donepezil alone, but the prescriber should still review the individual's full treatment plan.
How will we decide whether to continue?
Agree on a simple observation plan before treatment begins. Choose a few relevant abilities or symptoms, record the starting point, and identify who will report changes at follow-up. Ask the prescriber: Keep the dosing schedule, medication list, prescriber's number, and written instructions together where the person giving each dose can find them.
- When should the first treatment review occur?
- Which changes might show benefit?
- Which side effects should trigger a call?
- Under what circumstances would the dose change or treatment stop?
- Whom should the caregiver contact if several doses are missed?
